{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T15:01:06Z","timestamp":1775919666319,"version":"3.50.1"},"reference-count":13,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2013,11,20]],"date-time":"2013-11-20T00:00:00Z","timestamp":1384905600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2014,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Standard dosing for individuals with hemophilia A is based on body weight such that 50\u00a0IU\u00a0kg<jats:sup>\u22121<\/jats:sup> is defined as a 100% dose, or one attaining 1.00\u00a0IU\u00a0mL<jats:sup>\u22121<\/jats:sup> factor VIII (FVIII) clotting activity. No guidelines exist, however, for individuals with hemophilia who are obese, body mass index (<jats:styled-content style=\"fixed-case\">BMI<\/jats:styled-content>)\u00a0\u2265 30, who may actually be \u2018over\u2019\u2010treated based on higher in vivo recovery based on higher weight. Alternative treatment guidelines are needed for such patients. To determine FVIII pharmacokinetics we retrospectively collected data during ideal\u2010body\u2010weight dosing from six obese (<jats:styled-content style=\"fixed-case\">BMI<\/jats:styled-content>\u00a0\u2265\u00a030) hemophilia A patients cared for at the Hemophilia Center of Western <jats:styled-content style=\"fixed-case\">PA<\/jats:styled-content>, for prophylaxis or surgery. The pharmacokinetic data from six subjects undergoing ideal\u2010body\u2010weight dosing with recombinant FVIII indicate peak levels and half\u2010life comparable to standard 50\u00a0IU\u00a0kg<jats:sup>\u22121<\/jats:sup> dosing. The mean peak FVIII:C was 1.00\u00a0IU\u00a0dL<jats:sup>\u22121<\/jats:sup> and the mean FVIII:C half\u2010life was 10.14\u00a0h. IBW\u2010dosing resulted in an average 48.9% reduction in factor use per patient over a 3\u2010month period, for an annualized savings of $133\u00a0000 per patient. Ideal\u2010body\u2010weight dosing of recombinant FVIII in obese patients with hemophilia A results in comparable pharmacokinetics, including peak and half\u2010life, with comparable hemostatic efficacy for prophylaxis and surgical treatment, at a significant reduction in factor use and cost. Future studies are needed to confirm these findings in individuals with other congenital bleeding disorders and in children.<\/jats:p>","DOI":"10.1111\/hae.12300","type":"journal-article","created":{"date-parts":[[2013,11,20]],"date-time":"2013-11-20T10:35:36Z","timestamp":1384943736000},"page":"226-229","source":"Crossref","is-referenced-by-count":28,"title":["Pharmacokinetic analysis of anti\u2010hemophilic factor in the obese patient"],"prefix":"10.1111","volume":"20","author":[{"given":"A.","family":"Graham","sequence":"first","affiliation":[{"name":"Hemophilia Center of Western Pennsylvania Pittsburgh PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Jaworski","sequence":"additional","affiliation":[{"name":"Hemophilia Center of Western Pennsylvania Pittsburgh PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,11,20]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"Obesity and overweight for professionals: data and statistics: U.S. Obesity Trends.Atlanta GA:Division of Nutrition Physical Activity and Obesity National Center for Chronic Disease Prevention and Health Centers for Disease Control and Prevention. Available at:http:\/\/www.cdc.gov\/obesity\/data\/trends.html(Accessed August 25 2013)."},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1981.tb02722.x"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01332.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2008.03032.x"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1213\/ane.0b013e3181b0826a"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100381"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.21.4.575"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02370.x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12182"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.084038"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.19381"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02253.x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/1743-7075-4-19"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhae.12300","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.12300","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T15:26:43Z","timestamp":1695569203000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.12300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,20]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["10.1111\/hae.12300"],"URL":"https:\/\/doi.org\/10.1111\/hae.12300","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,20]]}}}